BIONEWS
The $2 Million Cure That's Exposing a Broken Payment System
The US has approved transformative gene therapies but lacks the financial infrastructure to deliver them at population scale — and no single actor can fix this alone.
The US has approved transformative gene therapies but lacks the financial infrastructure to deliver them at population scale — and no single actor can fix this alone.
The United States approved a $2 million cure for sickle cell disease. It did not build a way to pay for it.
That gap — between scientific capacity and financial infrastructure — is the central problem emerging in cell and gene therapy. The therapies work. The payment system was not designed for them.
Gene therapies like the ones now approved for sickle cell disease represent a fundamentally different model of medicine: a one-time treatment that can durably alter or replace a faulty biological process, potentially lasting a patient's entire life. The clinical case is compelling. The economics are not yet solved.
The core tension is structural. US healthcare financing is built around annual budgets and chronic disease payment cycles. Insurance plans, Medicaid programs, and hospital systems budget by the year. A $2 million one-time charge does not fit that frame. It is not an incremental cost increase; it is a category mismatch between when the expenditure happens and when the savings or outcomes materialize.
"The problem is not that the system cannot afford these therapies," William Padula, a scholar at the USC Schaeffer Center and the USC Mann School of Pharmacy, wrote in an opinion piece for STAT News. "It is that the system has not built the financial architecture to pay for them in a way that aligns incentives across manufacturers, providers, insurers, and states."
The CMS model and its limits
The Biden administration launched the Cell and Gene Therapy Access Model through the Centers for Medicare and Medicaid Services, a voluntary program designed to let state Medicaid agencies pool purchasing power and negotiate outcomes-based payment arrangements for gene therapies. States began joining between January 2025 and January 2026, with sickle cell disease as the initial focus.
The model is real and represents a genuine policy effort to improve access. But it operates within constraints that define its ceiling. As CMS describes the model, it is structured around multistate purchasing and outcomes-based arrangements — mechanisms that can improve access at the margins but do not restructure how upfront costs are financed. States remain bound by annual budget cycles. A therapy that costs $2 million in year one and generates savings across a decade still creates a budget problem in year one.
A USC Schaeffer Center white paper documents the gap: existing models, including the CGT Access Model, address individual financial risks through stop-loss insurance, drug mortgages, and value-based agreements but fail to align incentives across the system or ensure sustainable population-scale access. The instruments exist. The architecture does not.
The provider problem nobody talks about
One underappreciated barrier sits on the delivery side. Hospitals administering gene therapies can incur losses doing so. The reason: bundled reimbursement rates were built for a different era of medicine. A hospital that must absorb a $2 million drug cost while receiving a diagnosis-related group payment designed for chronic transfusion management is not indifferent to the financing gap. It is directly exposed.
Padula's research frames this as an infrastructure problem, not a pricing problem. The observable market behavior — manufacturers pricing high and treating relatively few patients rather than pursuing volume at lower prices — reflects delivery constraints, not pure profit maximization. Fix the financing infrastructure, the argument goes, and the pricing and volume behavior may shift accordingly.
What a mortgage model would actually require
Padula proposes third-party amortized financing vehicles: private capital funds treatment upfront, and repayment is tied to outcomes or downstream savings, analogous to how a mortgage spreads a large real estate purchase across a payoff timeline. The USC Schaeffer Center white paper sketches a stepwise reform path: private-market intermediation first, then public-private hybrid models, then direct public financing as a fallback.
The proposal is substantive and specific. It is also contested. Outcomes-based contracts — where payment is contingent on a patient staying well — sound clean in theory. In practice, tracking long-term outcomes across a patient's life, across employers and insurance transitions, and across state Medicaid programs is an administrative and legal challenge that has kept similar arrangements limited in scale.
FDA draft guidance intended to accelerate CGT development and review has moved faster in recent years. Faster approvals help patients reach therapies sooner. They do not resolve the financing gap, because approval is not the binding constraint.
Who is fighting over the answer
The contested terrain involves several actors whose incentives do not naturally align. Manufacturers want revenue certainty and are cautious about outcomes contracts that could expose them to refund obligations if therapies underperform. Insurers face actuarial uncertainty: a gene therapy approved for a 20-year-old might need to deliver value across five decades of coverage, and the contracts and capital reserves to underwrite that duration do not exist at scale. States managing Medicaid budgets have limited tools to spread a large upfront cost across future legislative sessions. Providers want to deliver care without absorbing unplanned losses. None of these parties is acting in bad faith. The problem is that the existing financial instruments were never designed for this situation.
The CGT Access Model represents an attempt to manage the problem through collective purchasing and outcomes-based arrangements. Whether it can scale sufficiently — and whether states will have the administrative capacity and manufacturer willingness to execute the model as designed — remains the open question.
What is clear is that lower list prices alone will not close the gap. Coverage expansions alone will not close it. The gap is architectural: it requires financial instruments, contractual frameworks, and possibly state or federal backstops that do not yet exist at the scale this class of medicine demands. The therapies are here. The plumbing is not.